← FDA Drug Approvals (Drugs@FDA)

XOLREMDI

NDA · New Drug Application · Sponsor: X4 PHARMS · Approved 2024-04-26

Drug application

FDA Application #

NDA218709

Application type

New Drug Application

Brand name

XOLREMDI

Generic name

MAVORIXAFOR

Active ingredients

MAVORIXAFOR

Dosage form

CAPSULE

Route

ORAL

Marketing status

Prescription

Sponsor

X4 PHARMS

Manufacturer

X4 Pharmaceuticals, Inc.

First approval

2024-04-26

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown